C. Bradley-Kennedy

Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.

J. Cramer, C. Bradley-Kennedy, A. Scalera, 2007, Canadian respiratory journal.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

S. Connolly, S. Sorensen, J. Plumb, 2011, Thrombosis and Haemostasis.

The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.

L. Kuramoto, N. Mittmann, J. Haddon, 2008, Respiratory medicine.

A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation

S. Sorensen, B. Monz, A. Kansal, 2013, PharmacoEconomics.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada

S. Sorensen, B. Monz, A. Kansal, 2012, Thrombosis and Haemostasis.

Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.

J. Cramer, C. Bradley-Kennedy, A. Scalera, 2007, Canadian respiratory journal.

Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients.

G. Ford, L. Kuramoto, J. M. FitzGerald, 2007, Canadian respiratory journal.